Endovascular Treatment With Versus Without Intravenous rhTNK-tPA in Stroke
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 550 participants.
Also called NCT04733742
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 550 participants
- Registry
-
NCT04733742
-
- Other papers using this trial's data
- Effect of Baseline ASPECTS on Tenecteplase Efficacy Before Thrombectomy in Acute Large-Vessel Occlusion Stroke: A Post Hoc Analysis of the BRIDGE-TNK Randomized Trial
- Intravenous Tenecteplase before Thrombectomy in Stroke
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT04733742. Randomized; single masking; primary purpose treatment. Start 2022-05-09 (actual); primary completion 2024-12-16 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Endovascular Treatment With Versus Without Intravenous rhTNK-tPA in Stroke
- Acronym
- BRIDGE-TNK
- Condition
- Stroke, Acute
- Condition
- Stroke, Ischemic
- Intervention (Drug)
- rhTNK-tPA
- Intervention (Other)
- Endovascular treatment
- Lead sponsor
- Xinqiao Hospital of Chongqing
- Collaborator
- CSPC RECOMGEN PHARMACEUTICAL (GUANGZHOU) CO.,LTD
Record details
- Record id
cardio:ct-nct04733742- Content hash
b81f0ad0656fd9fe02390b8acb9f53b76fbca1b32f03288090e80937e56651ff